(Q44985655)

8 December 2017

title

Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium (English)

1 reference

8 December 2017

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

1

John D Hainsworth

1 reference

8 December 2017

David M Waterhouse

2

1 reference

8 December 2017

William C Penley

3

1 reference

8 December 2017

Dianna L Shipley

4

1 reference

8 December 2017

Dana S Thompson

5

1 reference

8 December 2017

Charles D Webb

6

1 reference

8 December 2017

F Anthony Greco

7

1 reference

8 December 2017

publication date

24 April 2013

1 reference

8 December 2017

1 reference

8 December 2017

volume

31

1 reference

8 December 2017

issue

5

1 reference

8 December 2017

page(s)

323-329

1 reference

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.789900

10.3109/07357907.2013.789900

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference